Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)
Copyright policy )Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)
To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancer patients.A questionnaire was circulated among the members of the Breast International Group.A total of 277 oncologists from 28 countries participated in the survey. Seventy years is the age cut-off commonly used to define a patient as elderly. Biological age and the biological characteristics of the tumor are the most frequently used criteria to propose adjuvant chemotherapy to an elderly patient. Combination therapy with cyclophosphamide, methotrexate and fluorouracil on days 1 and 8 is the most frequently prescribed regimen. Great interest exists in oral chemotherapy.There is interest among those who responded to the survey to validate a comprehensive geriatric assessment for use as a predictive instrument of toxicity and/or activity of anticancer therapy and to evaluate the role of a treatment option that is potentially less toxic and possibly as effective as polychemotherapy.
- European Institute of Oncology Italy
- Université Libre de Bruxelles Belgium
- Institut Jules Bordet Belgium
- European Organisation for Research and Treatment of Cancer Netherlands
Cyclophosphamide -- administration & dosage, Aging, Methotrexate -- administration & dosage, Breast Neoplasms -- drug therapy, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols -- adverse effects, Medical Oncology, Medical Oncology -- statistics & numerical data, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Patient Care Planning, Predictive Value of Tests, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Physician's Practice Patterns -- statistics & numerical data, Breast Neoplasms -- surgery, Practice Patterns, Physicians', Cyclophosphamide, Geriatric Assessment, Adjuvant, Aged, Fluorouracil -- administration & dosage, Sciences bio-médicales et agricoles, Methotrexate, Chemotherapy, Adjuvant, Health Care Surveys, Female, Fluorouracil
Cyclophosphamide -- administration & dosage, Aging, Methotrexate -- administration & dosage, Breast Neoplasms -- drug therapy, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols -- adverse effects, Medical Oncology, Medical Oncology -- statistics & numerical data, Antineoplastic Combined Chemotherapy Protocols -- therapeutic use, Patient Care Planning, Predictive Value of Tests, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Humans, Physician's Practice Patterns -- statistics & numerical data, Breast Neoplasms -- surgery, Practice Patterns, Physicians', Cyclophosphamide, Geriatric Assessment, Adjuvant, Aged, Fluorouracil -- administration & dosage, Sciences bio-médicales et agricoles, Methotrexate, Chemotherapy, Adjuvant, Health Care Surveys, Female, Fluorouracil
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).55 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!